XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.2
STOCK CAPITAL (Tables)
6 Months Ended
Jun. 30, 2020
STOCK CAPITAL  
Schedule of fair value assumptions used for the stock options granted

Stock options fair value assumptions for the stock options granted during the six months ended June 30, 2020 are as follows:

For the six

months ended

June 30,

    

2020

Option life (years)

10

Risk free interest rate

0.36%-1.73%

Dividend yield

0

Expected volatility

58%-63%

Expected life (years)

5.04-5.50

years

Summary of the Company's option activity

A summary of the Company's option activity related to options to employees and directors, and related information as of June 30, 2020 is as follows:

For the Six months ended

June 30, 2020

    

    

Weighted

    

 

average

Aggregate

Amount of

exercise

intrinsic

options *

price

value

$

$

Outstanding at December 31, 2019

 

1,293,007

3.0142

 

Granted

 

618,666

6.4419

 

Exercised

 

(13,333)

3.0000

 

Cancelled

 

(4,000)

3.7500

 

Outstanding at June 30, 2020

 

1,894,340

4.1322

 

13,407,710

Exercisable at June 30, 2020

 

833,340

1.7276

 

7,902,051

*    Represents Employee Stock Options only (not including RSUs).

Schedule of compensation expense for restricted stock is based on fair market value at the grant date

    

    

    

Weighted Average

Remaining

Number of Shares

Weighted Average

Contractual

of Restricted

Grant Date Fair

Term

Stock

Value

(Years)

Nonvested as of December 31, 2019

 

201,385

 

4.00

 

1.95

Granted

 

134,613

 

6.24

 

Vested

 

37,297

 

3.81

 

Forfeitures

 

 

 

Nonvested as of June 30, 2020

 

298,701

 

5.03

 

1.45

Schedule of total stock-based compensation expense

The total stock-based compensation expense, related to shares, options and warrants granted to employees, directors and service providers was comprised, at each period, as follows:

Six months ended

June 30, 

    

2020

    

2019

Research and development

491

60

General and administrative

 

690

 

330

Total stock-based compensation expense

 

1,181

 

390